Contact Us
TEL: +86-0571-88334626
Home > News > Content
Daptomy Cin Description
Jun 11, 2018

Datoamycin was originally studied by Lilly Corporation and developed by Cubist Pharmaceutical Co., Ltd. as a link of fatty peptide antibiotics. In response to the patient's urgent need for new drug-resistant antibiotics, at the end of 2003, the U.S. Food and Drug Administration approved the rapid trial process for the injection of dacromycin(trade name cubicin) for the treatment of concurrent skin and skin structures caused by some Gram-positive sensitive strains. infection, Such as abscesses, surgical incision infections and skin ulcers. The mechanism of action of Dato mycin is different from that of other antibiotics. It hinders the biosynthesis of bacterial cell wall peptidoglycan by disrupting the transfer of amino acids to the cell membrane, and changes the properties of the cell plasmid membrane; In addition, it can also achieve sterilization by destroying the cell membrane of bacteria and releasing its contents. Therefore, it may be difficult for bacteria to develop resistance to dacomycin.